Hims & Hers CEO Andrew Dudum talks FTC lawsuit, GLP-1s, AI
CNBC • • business
Key Points:
- Hims & Hers CEO Andrew Dudum defended the company against an FTC lawsuit accusing it of improper data sharing, asserting the allegations stem from a misunderstanding of the company's innovative approach to healthcare.
- The FTC, along with Los Angeles County and Utah, sued Hims & Hers for sharing user health data with advertisers, charging for prescriptions before medical consultations, and making subscription cancellations difficult.
- Dudum emphasized the company's mission to disrupt healthcare by increasing access to care and highlighted their transition from compounded to branded GLP-1 drugs after resolving a patent dispute with Novo Nordisk.
- He forecasted significant price reductions for GLP-1 drugs for cash-paying patients, expecting costs to drop to $40-$50 per month from current prices of $150-$200.
- Dudum also stressed the importance of proprietary AI development in healthcare, stating Hims & Hers is investing in building in-house AI capabilities based on their unique closed-loop healthcare data.
